MX2021003797A - Terapias inmunoablativas. - Google Patents

Terapias inmunoablativas.

Info

Publication number
MX2021003797A
MX2021003797A MX2021003797A MX2021003797A MX2021003797A MX 2021003797 A MX2021003797 A MX 2021003797A MX 2021003797 A MX2021003797 A MX 2021003797A MX 2021003797 A MX2021003797 A MX 2021003797A MX 2021003797 A MX2021003797 A MX 2021003797A
Authority
MX
Mexico
Prior art keywords
immunoablative
therapies
diseases
treatment
compositions
Prior art date
Application number
MX2021003797A
Other languages
English (en)
Inventor
Theresa Deisher
Original Assignee
Avm Biotechnology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avm Biotechnology Llc filed Critical Avm Biotechnology Llc
Publication of MX2021003797A publication Critical patent/MX2021003797A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

Esta invención se relaciona con composiciones farmacéuticas que comprenden un glucocorticoide para utilizarse en el tratamiento de enfermedades mediante inmunoablación. Las composiciones de la invención se pueden utilizar en el tratamiento de enfermedades que son intervenidas por células inmunes tales como linfocitos.
MX2021003797A 2018-10-03 2019-10-03 Terapias inmunoablativas. MX2021003797A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18198491.5A EP3488851A1 (en) 2018-10-03 2018-10-03 Immunoablative therapies
PCT/US2019/054395 WO2020072713A1 (en) 2018-10-03 2019-10-03 Immunoablative therapies

Publications (1)

Publication Number Publication Date
MX2021003797A true MX2021003797A (es) 2021-08-11

Family

ID=63762311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003797A MX2021003797A (es) 2018-10-03 2019-10-03 Terapias inmunoablativas.

Country Status (14)

Country Link
US (2) US11446314B2 (es)
EP (2) EP3488851A1 (es)
JP (1) JP2020059703A (es)
KR (1) KR20210072039A (es)
CN (1) CN113164497A (es)
AU (1) AU2019355004A1 (es)
BR (1) BR112021006280A2 (es)
CA (1) CA3113969A1 (es)
EA (1) EA202190927A1 (es)
ES (1) ES2863369T3 (es)
MX (1) MX2021003797A (es)
SG (1) SG11202103031SA (es)
WO (1) WO2020072713A1 (es)
ZA (1) ZA202102727B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
KR20220130253A (ko) * 2018-11-14 2022-09-26 에이브이엠 바이오테크놀로지, 엘엘씨 안정한 글루코코르티코이드 제제
US20230096897A1 (en) * 2020-02-28 2023-03-30 Avm Biotechnology, Llc Lymphocyte Population and Methods for Producing Same
KR20230015927A (ko) 2020-04-29 2023-01-31 에이브이엠 바이오테크놀로지, 엘엘씨 Sars-cov-2 바이러스 치료를 위한 글루코코르티코이드 수용체(gr) 조절제
WO2021247000A1 (en) * 2020-06-01 2021-12-09 Avm Biotechnology, Llc Methods of treatment using icam-modulating agents
KR20220163638A (ko) 2021-06-03 2022-12-12 현대모비스 주식회사 차량용 제동장치 및 그 제어방법
EP4395784A1 (en) 2021-09-01 2024-07-10 AVM Biotechnology, LLC Lymphocyte population and methods for producing same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3368937A (en) * 1965-01-26 1968-02-13 Merck & Co Inc Injectable solid steroid-anesthetic
US4554271A (en) * 1984-02-24 1985-11-19 The Upjohn Company Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
JPH10507758A (ja) * 1994-10-19 1998-07-28 ジェネティック セラピー，インコーポレイテッド アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
EP1499347A2 (en) 2002-03-15 2005-01-26 Department of Veterans Affairs, Rehabilitation R&D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
EP1539240A2 (en) * 2002-05-02 2005-06-15 The Washington University Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
EP1502012A4 (en) * 2002-05-08 2009-07-01 Btu Int EXHAUST GAS TREATMENT OF A PLASMA ASSISTED ENGINE
CN102429908A (zh) 2002-05-17 2012-05-02 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
JP3968334B2 (ja) 2002-09-11 2007-08-29 株式会社日立ハイテクノロジーズ 荷電粒子線装置及び荷電粒子線照射方法
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
EP1835924B1 (en) 2004-12-23 2013-08-21 Ethicon, Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
SI1888033T1 (sl) * 2005-06-09 2014-06-30 Meda Ab Postopek in sestavek za zdravljenje vnetnih motenj
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
BRPI0613770A2 (pt) 2005-07-22 2009-05-19 Y S Therapeutics Co Ltd anticorpos anti-cd26 e métodos de uso destes
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
WO2008094689A2 (en) 2007-02-01 2008-08-07 Nephrogen, Llc Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
ES2627043T3 (es) 2008-06-09 2017-07-26 Targazyme, Inc. Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa
JP5537104B2 (ja) * 2009-09-16 2014-07-02 テルモ株式会社 制吐剤
SG187840A1 (en) 2010-08-18 2013-03-28 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
LT3214091T (lt) 2010-12-09 2018-12-10 The Trustees Of The University Of Pennsylvania Modifikuotų t ląstelių, turinčių chimerinį antigeno receptorių, panaudojimas vėžio gydymui
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
WO2013166026A1 (en) 2012-04-30 2013-11-07 Allocure, Inc. Methods of treating acute kidney injury using mesenchymal stem cells
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US11091543B2 (en) * 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
SG10201913604TA (en) 2015-05-28 2020-02-27 Kite Pharma Inc Methods of conditioning patients for t cell therapy
IL264502B2 (en) * 2016-08-29 2023-09-01 Tiziana Life Sciences Plc Anti-cd3 antibody formulations
CA3041434A1 (en) * 2016-10-24 2018-05-03 Novimmune Sa Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
WO2018153984A1 (en) * 2017-02-23 2018-08-30 Universität Bern Mtor inhibitor-corticoid combination therapy for multiple sclerosis
WO2018183927A1 (en) 2017-04-01 2018-10-04 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Also Published As

Publication number Publication date
ES2863369T3 (es) 2021-10-11
US11446314B2 (en) 2022-09-20
US20210338689A1 (en) 2021-11-04
KR20210072039A (ko) 2021-06-16
JP2020059703A (ja) 2020-04-16
SG11202103031SA (en) 2021-04-29
EP3860612A1 (en) 2021-08-11
WO2020072713A1 (en) 2020-04-09
ZA202102727B (en) 2022-05-25
US20200108078A1 (en) 2020-04-09
CA3113969A1 (en) 2020-04-09
US12048705B2 (en) 2024-07-30
EP3488851A1 (en) 2019-05-29
AU2019355004A1 (en) 2021-05-06
EA202190927A1 (ru) 2021-08-02
CN113164497A (zh) 2021-07-23
BR112021006280A2 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
MX2021003797A (es) Terapias inmunoablativas.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2024001394A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
NZ737399A (en) Ccr2 modulators
PH12016500094A1 (en) Autotaxin inhibitors
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
PH12016501791B1 (en) Muscarinic receptor agonists
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MX2018004883A (es) Composiciones farmaceuticas de il-2.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PH12019500024A1 (en) Pharmaceutical compositions
TW201613926A (en) Inhibitors of bruton's tyrosine kinase